The study from Tulane University found that those living in once-redlined neighborhoods see 15% longer delays in achieving successful viral suppression of HIV compared to those in non-redlined areas.

Tremendous successes have been achieved in treating and caring for people living with HIV and in developing HIV prevention technologies such as pre-exposure prophylaxis (PrEP) and post-exposure ...

Paxton has sued as the state is "cracking down" on health care providers who allegedly violate the state's ban on ...

and 5 trials in key populations across the U.S., U.K., and France. These studies are intended to contribute additional data in communities where the use of or access to prevention options have ...

Africa has about 25.9 million (65%) of the global burden with Nigeria contributing about 1.9 million making it the fourth ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Foster City, Calif.-based Gilead (GILD) had net income of $1.25 billion, or $1.00 a share, for the quarter, down from $2.18 billion, or $1.73 a share, in the year-earlier period. Adjusted for one-time ...

SYNC, its first homegrown CAR-T therapy, one of the first to show promise in treating certain types of brain cancers. This ...

The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.